METiS Pharmaceuticals Named Among BIOHK2024 'Top 5 to Watch' Ahead of Hong Kong IPO

Sep 18, 2024 16:42 CST Updated 16:42

METiS TechBio

AI-Driven Drug Formulation Developer

September 11-14, lasting for 4 daysBIOHK2024 Hong Kong International Biotechnology Forum and ExhibitionHeld at the Hong Kong Convention and Exhibition Centre. This year's conference witnessed an unprecedented scale, inviting over 200 industry leaders and academic experts, setting up more than 120 booths, and attracting over 2,600 registered professional attendees to explore the future development of biotechnology.

At the meeting,METiS PharmaceuticalsMETiS TechBio Co-Founder & CEO Dr. Lai Caida Delivered a Speech During the Roadshow Session. Meanwhile,With innovative technology, METiS TechBio stood out from fierce competition and was selected as one of the "BIOHK2024 Emerging Top 5" (Top 5 to Watch) companies.

BIOHK2024: The Grand Event in Asia's Biotechnology Field

BIOHK2024 is hosted by the Hong Kong Biotechnology Association,It is one of the largest international biotechnology conferences in Asia.The theme of BIOHK2024 is "Kaleidoscope," representing both the vast scope of biotechnology and the intersection and integration of various disciplines. Compared to the previous two editions, this year's exhibition has significantly improved in terms of scale, professionalism, and the range of topics covered.

This year's conference witnessed the presence of several heavyweight guests, including Mr. Leung Chun-ying, Vice Chairman of the Chinese People's Political Consultative Conference, Mr. Sun Dong, Secretary for Innovation, Technology and Industry of Hong Kong, Professor Albert Cheung-Hoi Yu, Chairman of the Hong Kong Biotechnology Association and BIOHK2024, Professor Nai-Ki Luk, Honorary Chairman of the Hong Kong Biotechnology Association, Dr. Charles Huang Ying-Hao, National People’s Congress Representative and Hong Kong Legislative Council Member, Mr. Tak-Chun Yau, Member of the Hong Kong Legislative Council, Sir Jonathan Symonds, Global Chairman of GSK, Ambassador George Hara, Chairman and CEO of DEFTA Partners Group, Professor George F. Gao, Academician of the Chinese Academy of Sciences, Professor Dennis Lo Yuk-Ming, Academician of the Chinese Academy of Sciences and President of the Hong Kong Academy of Sciences, Professor Wen-Dong Xu from Fudan University, recipient of the First Prize of the 2023 National Science and Technology Progress Award, Ms. Ada Chan Ka-Kei, CEO of Hong Kong Investment Management Limited, and others, jointly witnessing the opening of this grand event.

About“BIOHK2024Emerging Five"Strong" (Top 5 to Watch) RoadshowCompetition

The "BIOHK2024 Emerging Five" Roadshow Competition is an open selection event conducted in the format of a presentation followed by a Q&A session, with a judging panel composed of senior investors from the industry who will conduct rigorous scoring. Participating companies, after registering independently, were shortlisted by the organizing committee, resulting in a total of 52 startups making it to the competition, including seven enterprises from the Australian delegation.

The Selection Committee evaluated companies based on key metrics such as target market, competitiveness, corporate strategy, and financial status to identify outstanding performers with strong growth momentum and significant development potential. Fifty-two companies showcased their innovative products and technologies, making the competition intense and captivating. After a fierce contest, the following five companies were honored with the title of "BIOHK2024 Emerging Five Stars" (listed in alphabetical order):

AliveX Biotech
Genlight Medtech
Incando Therapeutics
METiS Pharmaceuticals（METiS TechBio）
NeoX Biotech

As one of the world's leading drug delivery platforms,METiS PharmaceuticalsIn the absence of open-source datasets and delivery-related algorithms, METiS TechBio started from scratch and innovatively developed groundbreaking artificial intelligence and computational simulation algorithms for the generation and design of ionizable lipids as well as the design and simulation of LNP nanomaterials. By integrating world-leading high-throughput experimental techniques and animal validation platforms, METiS TechBio has built its own data and algorithm barriers. It also established the world's first METiSLipidLM lipid language model and PhatGPT lipid generation model, creating a million-level lipid library, successfully breaking through international patent barriers.

At the same time, METiS TechBio combines innovative molecular simulation technology to simulate various microscopic processes of LNP in vivo and in vitro. Relying on a world-class experimental verification platform, it empowers the development of multi-organ targeted nanomaterials, achieving the successful implementation of AI + nanomaterial applications.